Posters & Publications

2022

Tourette C., Dioh W., Margalef C., Azbekyan A., Lafont R., Dilda P., Mariani J., Del Signore S., Agus S., Van Maanen R., Veillet S. (2022). Biophytis Ruvembri in Sarcopenia: results of the Phase 2 SARA-INT study. Oral presentation at 2^nd Geroscience Conference, Mar 24-25^th, Toulouse, France.

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022). Biophytis Ruvembri in Sarcopenia: Results of the SARA Program. Oral presentation at ICFSR 2022, Boston Apr 20^th – 22^nd. The Journal of Frailty & Aging, in press

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022). Ruvembri in age-related sarcopenia: Results of the SARA program. Oral presentation at 15^th SCWD international conference, Lisbon June 24^th-26^th. Journal of Cachexia, Sarcopenia and Muscle, in press

Veillet S. (2022). Discussing the use of Sarconeos (Ruvembri) for the treatment of an emerging age-related disease, Covid-19. 4th Annual Longevity Therapeutics Summit, June 28^th-30^th, San Francisco

Combination of Ruvembri with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like mice. Bézier C., Nazari Hashemi P., Cottin S., Lafont R., Veillet S., Charbonnier F., Dilda P.J., Latil M., Biondi O. Invited presentation at the Cure SMA 2022 conference in Anaheim, California, USA on June 16-19, 2022

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. Lafont R., Serova M., Didry-Barca B., Raynal S., Guibout L., Dinan L., S. Veillet, Latil M., Dioh W., Dilda P.J. Article published in  J. Mol. Endocrinol. 68(2), 77-87 https://jme.bioscientifica.com/view/journals/jme/68/2/JME-21-0033.xml

2021

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. Camelo S., Latil M., Agus S., Dioh W., Veillet S., Lafont R., Dilda P.J. Article published in Emerging Microbes and Infections, 10 (1): 2256-2263. https://doi.org/10.1080/22221751.2021.2006579.

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. Lafont R., Serova M., Didry-Barca B., Raynal S., Guibout L., Dinan L., S. Veillet, Latil M., Dioh W., Dilda P.J. (2021). Article published in J. Mol. Endocrinol, 68, 77-87. https://jme.bioscientifica.com/view/journals/jme/68/2/JME-21-0033.xml

Preclinical efficacy of Ruvembri on respiratory function in SARS-CoV-2-infected Syrian hamsters. Latil et al. Poster presented at 31^st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 9-12^th July 2021.

Ecysteroid metabolism in mammals: the fate of ingested 20-hydroxyecdysone in mice and rats. Dinan et al. Article published in Journal of Steroid Biochemistry and Molecular Biology, 212: 105896. https://doi.org/10.1016/j.jsbmb.2021.105896.

The complex metabolism of poststerone in male rats. Balducci et al. Published in Journal of Steroid Biochemistry and Molecular Biology. 212: 105897. https://doi.org/10.1016/j.jsbmb.2021.105897.

Testing the efficacy and safety of Ruvembri, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomized controlled trial. Dioh et al. Article published in Trials, 22:42.

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. Dinan et al. Article published in Biomedicines, 9 (5): 492. doi: 10.3390/biomedicines9050492.

Developing new drugs activating the protective arm of the Renin Angiotensin System as a potential treatment of respiratory failure in COVID-19 patients. Latil et al. Article published in Drug Discovery Today, 26 (5), 1311-1318.

2020

SARA program: the use of Ruvembri, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Tourette et al.

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al. Poster presented at 2nd International Summit on Aging & Gerontology (Aging & Gerontology-2020) 15-16th June, London, UK

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al. Poster presented at ICFSR 2020, 11-13 Mar, Toulouse, France

Small-scale analysis of phytoecdysteroids in seeds by HPLC/DAD/MS for the identification and quantification of specific analogues, dereplication and chemotaxonomy. Dinan et al. Article published in Phytochemical Analysis. Mar 17. doi: 10.1002/pca.2930.

Dietary phytoecdysteroids. Dinan et al. Chapter 5 of Handbook of Dietary Phytochemicals. J. Xiao et al. (eds.), Springer Nature Singapore Pte Ltd. 2020

2019

SARA program: preliminary findings from SARA-OBS study and impacts on the SARA-INT study design. Dioh et al. Oral presentation at SCWD conference on cachexia, sarcopenia and muscle wasting. December 6-8th, Berlin, Germany

Abstract published in Journal of Cachexia, Sarcopenia and Muscle

Preclinical characterization of Sarconeos (API Ruvembri) in Duchenne muscular dystrophy. Latil et al. Poster presentation at the 6^th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

Evaluation of safety and efficacy of Ruvembri, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial. Dioh et al. Oral presentation at 10^th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging.

Designing a clinical program for Ruvembri, a Mas receptor activator to target Age-related sarcopenia. Dioh et al. Oral presentation at 10^th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

The MYODA Operational Seamless clinical trial design phase I to III: A new approach for Rare Diseases to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Ruvembri (MAS Activator) in Pediatric Patients with a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy (DMD). Chabane et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark

Abstract published in Neuromuscular Disorders, 29, S1, S92, abstract P149

MYODA clinical program: Composite score for assessing the efficacy of Ruvembri (MAS activator) in ambulatory and non-ambulatory Duchenne boys. Chabane et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark

Abstract published in Neuromuscular Disorders, 29, S1, S178, abstract EP87

The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD. Chabane et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 460

In vivo effects of Sarconeos (API Ruvembri) on mouse model of severe spinal muscular atrophy. Belzier et al. Poster presentation at the 6^th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

MYODA clinical program: A new approach unravelling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages. Chabane et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 459

SARCONEOS (API Ruvembri) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting. Dilda et al. Oral presentation at 10^th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging, , 8 (S1), S14, abstract OC10

Ruvembri demonstrates combined beneficial effects on skeletal muscle and respiratory functions in a mouse model of Duchenne muscular dystrophy. Dilda et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark

Abstract published in Neuromuscular Disorders, 29, S1, S158, abstract P311

Ruvembri demonstrates combined beneficial effects on muscle and motor neurons in a mouse model of severe spinal muscular atrophy. Latil et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark.

Abstract published in Neuromuscular Disorders, 29, S1, S189, abstract P370

Preclinical characterization of Sarconeos (API Ruvembri) in Duchenne muscular dystrophy. Latil et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 351

In vivo effects of Sarconeos (API Ruvembri) on mouse model of severe spinal muscular atrophy. Bézier et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 277

2018

Ruvembri accelerates differentiation and enhances mitochondrial function in skeletal muscle cells. Serova et al. Oral presentation at the 11^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018; 9; 1170. Abstract 4-11.

Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (Ruvembri). Dioh et al. Oral presentation at the 11^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018 Dec; 9(6); 1172. Abstract 5-01.

Effects of Sarconeos (API Ruvembri) on in vivo and in vitro models of Duchenne muscular dystrophy. Dilda et al. Poster presentation at the 23^rd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2018, Mendoza, Argentina.

Abstract published in Neuromuscular Disorders, 28 (Suppl.2) S143, P206.

Combined effects of Ruvembri on anabolism and mitochondrial function in skeletal muscle cells. Serova et al. Oral and poster presentations at the 9^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 72. Abstract OC12.

SARA-INT, A double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (Ruvembri). Dioh et al. Poster presentation at the 9^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

SARA-OBS, an observational study dedicated to characterize Age-related Sarcopenia population suitable for interventional studies. Dioh et al. Oral presentation at the 9^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 72. Abstract OC44.

Daily Mobility profile in Age-Related Sarcopenia: Actimetry baseline data from SARA-OBS, a six-month observational multicentre clinical study in EU and US. Zia et al. Poster presentation at the 9^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 128. Abstract P110.

BIO103 demonstrates sharp improvement of skeletal muscle function in an animal model of hindlimb immobilization. Latil et al. Poster presentation at the 9^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 128-129. Abstract P113.

2017

BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09.

SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial. Dioh et al. Poster presentation at the 10^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1073-1074. Abstract 9-02.

Sarconeos, a drug candidate in clinical development for Sarcopenia, demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy. Dilda et al. Poster presentation at the 22^nd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2017, Saint Malo, France.

BIO103, a second-generation compound for the treatment of sarcopenia. From anabolic properties to the reversion of aging-related functional loss. Dilda et al. Poster presentation at the 8^th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging. 6(S1), 146, Abstract 217.

SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of Ruvembri in healthy young and older volunteers. Dioh et al. Oral and poster presentations at the 8^th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging. 6(S1), 28, Abstract OC38.

2016

Ruvembri, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. Dilda et al. Poster presentation at the 9^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 7(5), 655. Abstract 4-01.

A randomized, placebo-controlled trial to evaluate the efficacy and safety of Ruvembri on Sarcopenic Obesity. Dioh et al. Poster presentation at the 7^th International Conference on Frailty & Sarcopenia Research (ICFSR), April 28-29, 2016, Philadelphia, USA.

Abstract published in The Journal of Frailty & Aging, 5, S1, 75, Abstract P53.

2015

Ruvembri, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8^th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.

2014

The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5^th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.